

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/016383-2023>

Planning

Licensed Bulk Medicines

Velindre NHS Trust, NHS Wales Shared Services Partnership — Procurement Services
(on behalf of All Wales LHB's and Trusts)

F01: Prior information notice

Prior information only

Notice identifier: 2023/S 000-016383

Procurement identifier (OCID): ocds-h6vhtk-03d4f5

Published 9 June 2023, 10:24am

Section I: Contracting authority

I.1) Name and addresses

Velindre NHS Trust, NHS Wales Shared Services Partnership — Procurement Services
(on behalf of All Wales LHB's and Trusts)

Procurement Services, 4th Floor, Companies House, Crown Way

Cardiff

CF14 3UB

Email

Theo.davies@wales.nhs.uk

Telephone

+44 2920903883

Country

United Kingdom

Region code

UKL - Wales

Internet address(es)

Main address

<https://etenderwales.bravosolution.co.uk/>

Buyer's address

<https://nwssp.nhs.wales/ourservices/procurement-services/>

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

Additional information can be obtained from the above-mentioned address

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Licensed Bulk Medicines

II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.1.4) Short description

We are interested in buying the following list of products, in licensed bulk containers of up to the sizes noted below, to be available within a 5 year timeframe. We consider the availability in licensed bulk presentation to be a significant market advantage and are willing to consider entering contracts for supply with suppliers who can meet this presentation requirement for these products.

Estimated value in the Wales market of this list is £42,317,736.61 p/a at current prices.

The list is not exhaustive, and we are willing to consider other generic and biosimilar products if licensed bulk presentation can be offered.

Drug, Strength, Proposed Vial Size

ARSENIC TRIOXIDE, 1mg/mL,

AZACITIDINE, 25mg/mL, 500mL

BEVACIZUMAB, 25mg/mL, 100mL - 250mL

BORTEZOMIB, 2.5mg/mL, 50mL

CALCIUM FOLINATE, 10mg/mL, 1000mL

CARBOPLATIN, 10mg/mL, 1000mL

CETUXIMAB, 5mg/mL, 250m – 500mL

CISPLATIN,1mg/mL,500mL - 1000mL

CYCLOPHOSPHAMIDE,20mg/mL,500mL

CYTARABINE,100mg/mL or 20mg/mL,250mL

DARATUMUMAB,20mg/mL,100mL – 250mL

DOCETAXEL,20mg/mL,250mL - 500mL

DOXORUBICIN,2mg/mL,1000mL

EPIRUBICIN,2mg/mL,1000mL

ETOPOSIDE,20mg/mL,500mL

FLUCLOXACILLIN,,3000mL

FLUOROURACIL,50mg/mL or 25mg /mL,250-500mL

INFLIXIMAB,10mg/mL,500mL - 1000mL

IRINOTECAN,20mg/mL,1000mL

NIVOLUMAB,10mg/mL,250mL

OXALIPLATIN,5mg/mL,500mL-1000mL

PACLITAXEL,6mg/mL,1000mL

PEMBROLIZUMAB,25mg/mL,100mL – 250mL

PEMETREXED,25mg/mL,100mL – 250mL

PIPERACILLIN & TAZOBACTAM,,3000mL

RITUXIMAB,10mg/mL,500mL

TOCILIZUMAB,20mg/mL,250mL

TRASTUZUMAB EMTANSINE,20mg/mL,100mL - 250mL

VEDOLIZUMAB,60mg/mL,250mL

VITLIPID N INFANT,N/A,250mL

Please inform us via the contact information above if you are able to provide these products.

II.1.5) Estimated total value

Value excluding VAT: £42,317,736.61

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKL - Wales

II.2.4) Description of the procurement

We are interested in buying the following list of products, in licensed bulk containers of up to the sizes noted below, to be available within a 5 year timeframe. We consider the availability in licensed bulk presentation to be a significant market advantage and are willing to consider entering contracts for supply with suppliers who can meet this presentation requirement for these products.

Estimated value in the Wales market of this list is £42,317,736.61 p/a at current prices.

The list is not exhaustive, and we are willing to consider other generic and biosimilar products if licensed bulk presentation can be offered.

Drug,Strength,Proposed Vial Size

ARSENIC TRIOXIDE,1mg/mL,

AZACITIDINE,25mg/mL,500mL

BEVACIZUMAB,25mg/mL,100mL - 250mL

BORTEZOMIB,2.5mg/mL,50mL

CALCIUM FOLINATE,10mg/mL,1000mL

CARBOPLATIN,10mg/mL,1000mL

CETUXIMAB,5mg/mL,250m – 500mL

CISPLATIN,1mg/mL,500mL - 1000mL

CYCLOPHOSPHAMIDE,20mg/mL,500mL

CYTARABINE,100mg/mL or 20mg/mL,250mL

DARATUMUMAB,20mg/mL,100mL – 250mL

DOCETAXEL,20mg/mL,250mL - 500mL

DOXORUBICIN,2mg/mL,1000mL

EPIRUBICIN,2mg/mL,1000mL

ETOPOSIDE,20mg/mL,500mL

FLUCLOXACILLIN,,3000mL

FLUOROURACIL,50mg/mL or 25mg /mL,250-500mL

INFLIXIMAB,10mg/mL,500mL - 1000mL

IRINOTECAN,20mg/mL,1000mL

NIVOLUMAB,10mg/mL,250mL

OXALIPLATIN,5mg/mL,500mL-1000mL

PACLITAXEL,6mg/mL,1000mL

PEMBROLIZUMAB,25mg/mL,100mL – 250mL

PEMETREXED,25mg/mL,100mL – 250mL

PIPERACILLIN & TAZOBACTAM,,3000mL

RITUXIMAB,10mg/mL,500mL

TOCILIZUMAB,20mg/mL,250mL

TRASTUZUMAB EMTANSINE,20mg/mL,100mL - 250mL

VEDOLIZUMAB,60mg/mL,250mL

VITLIPID N INFANT,N/A,250mL

Please inform us via the contact information above if you are able to provide these products.

II.3) Estimated date of publication of contract notice

1 January 2025

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes